TX-PLANVIEW
18.5.2022 15:02:10 CEST | Business Wire | Press release
Planview, a global leader in Portfolio Management and Work Management, today announced that the company has entered into a definitive agreement to acquire Tasktop, a pioneer and leader in Value Stream Management (VSM). Based in Vancouver, Canada, Tasktop has 200+ employees and in FY21 saw record growth with 43% year-over-year user expansion.
“As companies strive to differentiate, survive, thrive, and disrupt their markets, there is a surge in digitalization and transformation initiatives. While well-intended, the facts show that most digital transformation efforts fail to achieve value for the business,” said Razat Gaurav, Chief Executive Officer at Planview. “Together, we provide an exciting and much needed capability that will help our customers to connect the business of software delivery – enabling them to efficiently transform their organizations faster with more confidence, and a better ability to achieve desired business outcomes.”
“Connecting Planview’s leadership in enterprise Agile and strategic portfolio management with Tasktop’s leadership in VSM is a game-changing combination that expands the capabilities and value proposition we can offer to customers. Tasktop and Planview’s complementary offerings will better help our customers realize digital transformation – accelerating the pace at which they can transform and deliver competitive advantages through technology,” said Mik Kersten, Founder and Chief Executive Officer at Tasktop. “Tasktop and Planview have more than eight years of history working together, and we’re thrilled to be taking this next step in our relationship to join forces and make it possible for every organization to become a digital innovator.”
The acquisition of Tasktop is part of Planview’s strategy to build the future of connected work and deliver transformative solutions. Together, Planview and Tasktop will empower organizations to accelerate their time to market, improve operational efficiency and drive investment confidence in the face of economic disruption and instability. In the past year, Tasktop’s solutions have played a critical part of some of the world’s most successful digital transformations, including BMW, HSBC, Kaiser Permanente, T-Mobile and TUI Group. Similarly, Planview has added marquee global customers such as ADP, AT&T, IBM, FIFA, and Standard Chartered.
Leading industry analyst firms like Forrester1 point to the benefits of integrating Strategic Portfolio Management (SPM) and VSM. According to Forrester, “Building genuine business agility requires having the necessary information at hand to make pivot or persevere decisions. When SPM is integrated with delivery systems such as value stream management (VSM), it provides visibility into actual performance to support change decisions.”1
Upon completion of the transaction, the Tasktop team will join Planview, bringing additional expertise and thought leadership around VSM. Kersten will serve as Chief Technology Officer. The transaction is expected to close mid-Summer of 2022, pending regulatory approval. Terms of the transaction were not disclosed.
1 Forrester, Now Tech: Strategic Portfolio Management Tools, Q3 2021, Margo Visitacion, August 19, 2021.
About Planview
Planview has one mission: to build the future of connected work. Our solutions enable organizations to connect the business from ideas to impact, empowering companies to accelerate the achievement of what matters most. Planview’s full spectrum of Portfolio Management and Work Management solutions creates an organizational focus on the strategic outcomes that matter and empowers teams to deliver their best work, no matter how they work. The comprehensive Planview platform and enterprise success model enables customers to deliver innovative, competitive products, services, and customer experiences. Headquartered in Austin, Texas, with locations around the world, Planview has more than 1,000 employees supporting 4,000 customers and 2.4 million users worldwide. For more information, visit www.planview.com .
About Tasktop
Tasktop's value stream management platform enables enterprises to master software at scale. Leading brands, including half of the Fortune 100, use Tasktop to provide real-time visibility into the health of product value streams, allowing them to make better decisions and align with business goals. Tasktop connects with existing third party tools businesses are already using and overlays the end-to-end value stream to provide the abstractions, automations, visualizations and forensics needed to practice value stream management on a daily basis. Learn more about Tasktop at tasktop.com and follow us on Twitter @tasktop.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220517006293/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom